BRANFORD, Conn., June 14 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN - News) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with cis-retinoic acid for the treatment of patients with advanced solid tumors. This trial is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen for PXD101.
